Arunjyoti Bio Ventures Limited held its Board of Directors meeting on 13.05.2026 at its registered office in Madhapur, Hyderabad. The board considered and approved the audited financial results for the quarter and year ended 31 March 2026, along with the Auditor's Report. The board also approved the write-off of outstanding debtors and creditors amounting to Rs. 2,73,64,542/- in the books of accounts of the company. The meeting commenced at 04:15 P.M. and concluded at 05:45 P.M.

Financial Performance: Quarter and Year Ended 31 March 2026

The company's revenue from operations for Q4FY26 stood at ₹723.73 lakhs, compared to ₹646.82 lakhs in Q3FY26 and ₹528.10 lakhs in Q4FY25. For the full year, revenue from operations was ₹2,775.44 lakhs against ₹2,788.41 lakhs in the previous year. The following table summarises the key financial results:

Employee benefit expenses rose sharply to ₹1,123.49 lakhs for FY26 compared to ₹134.72 lakhs in FY25. Finance costs declined to ₹204.73 lakhs in FY26 from ₹893.12 lakhs in FY25. Depreciation and amortisation expenses for FY26 stood at ₹335.81 lakhs versus ₹258.87 lakhs in the prior year.

Exceptional Items

The company recognised exceptional items totalling ₹273.65 lakhs during Q4FY26 and for the full year FY26. These comprised bad debts written off and advances to vendors written off, as detailed below:

Additionally, certain operational bottlenecks and process inefficiencies during Q4FY26 resulted in abnormal consumption of inventory amounting to Rs. 241 lakhs, recognised under consumption of stores and consumables for the quarter and year ended 31 March 2026.

Balance Sheet Highlights

The company's total assets as at 31 March 2026 stood at ₹5,416.29 lakhs, compared to ₹6,138.76 lakhs as at 31 March 2025. Total equity declined to ₹2,871.81 lakhs from ₹3,325.42 lakhs in the prior year. Key balance sheet figures are presented below:

Cash Flow Summary

Net cash generated from operating activities for the year ended 31 March 2026 was ₹1,036.40 lakhs, compared to ₹161.85 lakhs in the previous year. Net cash used in investing activities was ₹484.40 lakhs, while net cash used in financing activities was ₹598.55 lakhs. Cash and cash equivalents at the end of the year stood at ₹12.67 lakhs, down from ₹59.22 lakhs at the beginning of the year.

Prior Period Restatement and Auditor's Report

During the year, the company identified and corrected a prior period error relating to deferred tax on depreciation differences and recognition of previously unavailed tax benefit on unabsorbed depreciation. In accordance with Ind AS 8, comparative figures have been restated; the adjustment is non-cash in nature and has no impact on the company's operating performance or cash flows. The statutory auditors, PKF Sridhar & Santhanam LLP (Firm Registration No. 003990S/S200018), issued an unmodified audit opinion on the standalone audited financial results for the quarter and year ended 31 March 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The auditors drew attention to the restatement of deferred tax computation and the write-off of certain balances amounting to Rs. 273.65 lakhs, though their opinion was not modified in respect of these matters. The declaration of unmodified opinion was submitted by Whole-Time Director P.B.N. Murthy (DIN: 01445523) on behalf of the board.

Arunjyoti Bio Ventures Limited has announced the postponement of its Board Meeting, which was originally scheduled for May 8, 2026. The meeting has been rescheduled to May 12, 2026, due to unavoidable reasons. The intimation regarding this change was communicated to BSE Limited on May 5, 2026, referencing the earlier notice dated May 1, 2026.

Revised Meeting Details

The board meeting will now take place at the company's registered office. The venue and logistical details remain consistent with the original plan, ensuring a formal setting for the directors to deliberate on key financial matters.

Agenda Items

The agenda for the rescheduled meeting remains unchanged. The board will focus on the primary items essential for the company's regulatory compliance and strategic planning:

• Audited Financial Results: Review and approval of audited financial results for the quarter and year ended March 31, 2026
• Additional Business: Consideration of any other business matters with the permission of the Chair

Regulatory Compliance

The intimation was digitally signed by P.B.N. Murthy, Whole-Time Director (DIN: 01445523). This communication ensures transparency and keeps stakeholders informed about the change in schedule. The company continues to adhere to corporate governance standards by promptly notifying the stock exchange of the postponement.

This rescheduled meeting allows Arunjyoti Bio Ventures Limited the necessary time to prepare for the presentation of its annual financial performance to stakeholders and fulfill its regulatory obligations for the fiscal year 2026.